Cite
Bain EE, Shafner L, Walling DP, et al. Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia. JMIR Mhealth Uhealth. 2017;5(2):e18doi: 10.2196/mhealth.7030.
Bain, E. E., Shafner, L., Walling, D. P., Othman, A. A., Chuang-Stein, C., Hinkle, J., & Hanina, A. (2017). Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia. JMIR mHealth and uHealth, 5(2), e18. https://doi.org/10.2196/mhealth.7030
Bain, Earle E, et al. "Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia." JMIR mHealth and uHealth vol. 5,2 (2017): e18. doi: https://doi.org/10.2196/mhealth.7030
Bain EE, Shafner L, Walling DP, Othman AA, Chuang-Stein C, Hinkle J, Hanina A. Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia. JMIR Mhealth Uhealth. 2017 Feb 21;5(2):e18. doi: 10.2196/mhealth.7030. PMID: 28223265; PMCID: PMC5340925.
Copy
Download .nbib